High-resolution analysis of genomic profiles of hepatocellular carcinoma cells with differential osteopontin expression

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 387-391

  Sun, Bingsheng ^a   Wu, Jincai ^b   Zhang, Ti ^a   Wang, Changli ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Array CGH; Chromosomal aberration; Hepatocellular carcinoma; Immunohistochemistry; Metastasis; Osteopontin; Tumor heterogeneity

Indexed keywords

OSTEOPONTIN;

ARTICLE; CANCER CELL CULTURE; CHROMOSOME 13Q; CHROMOSOME 4Q; CLDN10 GENE; COMPARATIVE GENOMIC HYBRIDIZATION; EPHA5 GENE; GENE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MUC7 GENE; PROTEIN EXPRESSION; SMR3B GENE; SPP1 GENE; CHROMOSOME MAP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; NUCLEIC ACID HYBRIDIZATION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMOSOME MAPPING; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OSTEOPONTIN;

EID: 50949112936     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5365     Document Type: Article

References (34)

1. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52:19-24.
2. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23.
3. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101:2051-9.
4. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98:119-27.
5. Carlinfante G, Vassiliou D, Svensson O, Wendel M, Heinegard D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003; 20:437-44.
6. Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006; 66:883-8.
7. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, et al. Osteopontin: Possible role in prostate cancer progression. Clin Cancer Res 1999; 5:2271-7.
8. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62:3417-27.
9. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10:184-90.
10. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94:513-21.
11. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as colon cancer tumor progression marker. C R Biol 2003; 326:1041-3.
12. Sedivy R, Peters K, Kloppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005; 446:41-5.
13. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13:487-91.
14. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, et al. Enhanced production of osteopontin in multiple myeloma: Clinical and pathogenic implications. Br J Haematol 2003; 123:263-70.
15. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90:1877-81.
16. Tuck AB, Arsenault DM, O'malley FP, Hota C, Ling MC, Wilson SM, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18:4237-46.
17. Ariztia EV, Subbarao V, Solt DB, Rademaker AW, Iyer AP, Oltvai ZN. Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation. Exp Cell Res 2003; 288:257-67.
18. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:709-17.
19. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996; 1314:13-24.
20. Denhardt DT, Noda M, O'regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055-61.
21. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17:1-15.
22. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14:1581-8.
23. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996; 13:97-104.
24. Denhardt DT, Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 1998; 30?31:92-102.
25. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259-73.
26. Wang X, Fan M, Chen X, Wang S, Alsharif MJ, Wang L, et al. Intratumor genomic heterogeneity correlates with histological grade of advanced oral squamous cell carcinoma. Oral Oncol 2006; 42:740-4.
27. Huang J, Sheng HH, Shen T, Hu YJ, Xiao HS, Zhang Q, et al. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett 2006; 580:3571-81.
28. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007; 282:5413-9.
29. Retz M, Lehmann J, Szysnik C, Zwank S, Venzke T, Roder C, et al. Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR. Eur Urol 2004; 45:314-9.
30. Kinjo M, Okegawa T, Horie S, Nutahara K, Higashihara E. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol 2004; 11:38-43.
31. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: Ephrin gene expression correlates with shortened survival. BMC Cancer 2006; 6:144.
32. Campbell TN, Attwell S, Arcellana-Panlilio M, Robbins SM. Ephrin A5 expression promotes invasion and transformation of murine fibroblasts. Biochem Biophys Res Commun 2006; 350:623-8.
33. Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcene A. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 2006; 118:850-6.
34. Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, Ng IO, et al. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 2005; 11:551-6.